专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012177481A3 FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITION FOR THE TREATMENT OF DISEASE 审中-公开
标题翻译： FIBROBLAST生长因子受体抑制疾病的治疗
公开(公告)号：WO2012177481A3
公开(公告)日：2014-05-08
申请号：PCT/US2012042449
申请日：2012-06-14
申请人： UNIV MIAMI , FAUL CHRISTIAN , WOLF MYLES
发明人： FAUL CHRISTIAN , WOLF MYLES
IPC分类号： C12N15/113 , A61K39/395 , C12P21/00
CPC分类号： A61K39/3955 , A61K38/179 , C07K14/71 , C07K16/2863 , C07K2319/31 , C07K2319/32 , C12N15/1138 , C12Q1/6876 , G01N33/53
摘要： Methods of inhibiting fibroblast growth factor mediated activation of fibroblast growth factor receptors for the treatment of chronic kidney disease, diabetes, and cardiac diseases are enclosed. Pharmaceutical compositions for the treatment of such diseases using the methods are also disclosed as are methods of determining whether a subject would benefit from the methods of treatment and pharmaceutical compositions.
摘要翻译：包封抑制成纤维细胞生长因子介导的成纤维细胞生长因子受体激活治疗慢性肾脏疾病，糖尿病和心脏病的方法。还公开了用于使用这些方法治疗这些疾病的药物组合物，是确定受试者是否将受益于治疗方法和药物组合物的方法。

2. 发明申请

WO2009091556A2 DIAGNOSTIC METHODS AND KITS USING FIBROBLAST GROWTH FACTOR-23 审中-公开
标题翻译：诊断方法和使用成纤维细胞生长因子的工具23
公开(公告)号：WO2009091556A2
公开(公告)日：2009-07-23
申请号：PCT/US2009000234
申请日：2009-01-15
申请人： GEN HOSPITAL CORP , WOLF MYLES
发明人： WOLF MYLES
IPC分类号： G01N33/68 , G01N33/50
CPC分类号： G01N33/74 , G01N2333/50 , G01N2800/347
摘要： The present invention describes the ability to identify chronic kidney disease (CKD) mortality risk in asymptomatic patients. For example, a patient having a normal glomerular filtration rate would be considered likely to have an increased mortality risk for chronic kidney disease upon the detection of an FGF-23 amino acid sequence that is above a normal level, but below CKD Stage 1 levels. Consequently, therapeutic strategies may be implements to prevent morbidity and mortality following chronic kidney disease progression. Such therapeutic strategies can involve phosphate reduction strategies (i.e., for example, reduced dietary intake of phosphorus and/or administration of phosphate binding compound). Further, kits are described providing instruction to determine a specific mortality risk based upon measured FGF-23 levels and estimated glomerular filtration rates.
摘要翻译：本发明描述了在无症状患者中识别慢性肾脏疾病（CKD）死亡率风险的能力。例如，具有正常肾小球滤过率的患者在检测到高于正常水平但低于CKD阶段1水平的FGF-23氨基酸序列时，可能对慢性肾脏疾病具有增加的死亡风险。因此，可以实施治疗策略以预防慢性肾脏疾病进展后的发病率和死亡率。这样的治疗策略可以涉及磷酸盐还原策略（例如，减少磷的膳食摄取和/或施用磷酸盐结合化合物）。此外，描述了试剂盒，其提供了基于测量的FGF-23水平和估计的肾小球滤过率来确定特定死亡率风险的指导。

3. 发明申请

WO2005017192A2 SCREENING FOR GESTATIONAL DISORDERS 审中-公开
标题翻译：筛查呕吐障碍
公开(公告)号：WO2005017192A2
公开(公告)日：2005-02-24
申请号：PCT/US2004026484
申请日：2004-08-16
申请人： GEN HOSPITAL CORP , THADHANI RAVI , WOLF MYLES , KNICKERBOCKER TANYA LYNN , MACBEATH GAVIN
发明人： THADHANI RAVI , WOLF MYLES , KNICKERBOCKER TANYA LYNN , MACBEATH GAVIN
IPC分类号： G01N33/53 , G01N33/68 , G06F19/20 , C12Q1/00 , C12Q1/44 , C12Q1/68 , G01N33/543 , G01N33/567
CPC分类号： G01N33/689 , G01N2333/505 , G01N2333/52 , G01N2333/525 , G01N2333/53 , G01N2333/54 , G01N2333/555 , G01N2333/5756 , G01N2333/61 , G01N2800/368 , G06F19/20 , Y10S436/811
摘要： The invention relates to methods and compositions for identifying pregnant subjects having, or predisposed to having, gestational diabetes, preeclampsia, and gestational hypertension. The methods are applicable to urine and/or blood samples and can be conducted prior to the third trimester of pregnancy, and as early as the first trimester.
摘要翻译：本发明涉及用于鉴定具有妊娠糖尿病，先兆子痫和妊娠高血压患有或倾向于具有妊娠糖尿病，先兆子痫和妊娠高血压的怀孕受试者的方法和组合这些方法适用于尿液和/或血液样品，可以在妊娠前三个月，早在妊娠前期进行。

4. 发明申请

WO2012177481A2 FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITION FOR THE TREATMENT OF DISEASE 审中-公开
标题翻译： FIBROBLAST生长因子受体抑制疾病的治疗
公开(公告)号：WO2012177481A2
公开(公告)日：2012-12-27
申请号：PCT/US2012/042449
申请日：2012-06-14
申请人： UNIVERSITY OF MIAMI , FAUL, Christian , WOLF, Myles
发明人： FAUL, Christian , WOLF, Myles
IPC分类号： A61K48/00 , A61K38/17
CPC分类号： A61K39/3955 , A61K38/179 , C07K14/71 , C07K16/2863 , C07K2319/31 , C07K2319/32 , C12N15/1138 , C12Q1/6876 , G01N33/53
摘要： Methods of inhibiting fibroblast growth factor mediated activation of fibroblast growth factor receptors for the treatment of chronic kidney disease, diabetes, and cardiac diseases are enclosed. Pharmaceutical compositions for the treatment of such diseases using the methods are also disclosed as are methods of determining whether a subject would benefit from the methods of treatment and pharmaceutical compositions.
摘要翻译：包封抑制成纤维细胞生长因子介导的成纤维细胞生长因子受体激活治疗慢性肾脏疾病，糖尿病和心脏病的方法。还公开了用于使用这些方法治疗这些疾病的药物组合物，是确定受试者是否将受益于治疗方法和药物组合物的方法。

5. 发明申请

WO2009091556A3 DIAGNOSTIC METHODS AND KITS USING FIBROBLAST GROWTH FACTOR-23 审中-公开
公开(公告)号：WO2009091556A3
公开(公告)日：2009-07-23
申请号：PCT/US2009/000234
申请日：2009-01-15
申请人： THE GENERAL HOSPITAL CORPORATION , WOLF, Myles
发明人： WOLF, Myles
IPC分类号： G01N33/68 , G01N33/50
摘要： The present invention describes the ability to identify chronic kidney disease (CKD) mortality risk in asymptomatic patients. For example, a patient having a normal glomerular filtration rate would be considered likely to have an increased mortality risk for chronic kidney disease upon the detection of an FGF-23 amino acid sequence that is above a normal level, but below CKD Stage 1 levels. Consequently, therapeutic strategies may be implements to prevent morbidity and mortality following chronic kidney disease progression. Such therapeutic strategies can involve phosphate reduction strategies (i.e., for example, reduced dietary intake of phosphorus and/or administration of phosphate binding compound). Further, kits are described providing instruction to determine a specific mortality risk based upon measured FGF-23 levels and estimated glomerular filtration rates.

6. 发明申请

WO2007001969A1 VITAMIN D DEFICIENCY AND DIALYSIS 审中-公开
标题翻译：维生素D缺乏和分析
公开(公告)号：WO2007001969A1
公开(公告)日：2007-01-04
申请号：PCT/US2006/023774
申请日：2006-06-19
申请人： THE GENERAL HOSPITAL CORPORATION , THADHANI, Ravi , WOLF, Myles
发明人： THADHANI, Ravi , WOLF, Myles
IPC分类号： A01N45/00
CPC分类号： G01N33/82 , G06F19/00
摘要： The invention includes methods and kits for reducing the risk of mortality of dialysis by assaying endogenous vitamin D levels in the serum or plasma of a dialysis patient or a patient in need of dialysis, comparing the endogenous vitamin D levels to a threshold level; and providing exogenous vitamin D (e.g., activated vitamin D) to patients with endogenous vitamin D levels below the threshold level.
摘要翻译：本发明包括通过测定透析患者或需要透析的患者的血清或血浆中的内源性维生素D水平来比较内源性维生素D水平与阈值水平来降低透析死亡风险的方法和试剂盒; 并向具有低于阈值水平的内源性维生素D水平的患者提供外源性维生素D（例如活化的维生素D）。

7. 发明申请

WO2005017192A3 SCREENING FOR GESTATIONAL DISORDERS 审中-公开
公开(公告)号：WO2005017192A3
公开(公告)日：2005-02-24
申请号：PCT/US2004/026484
申请日：2004-08-16
申请人： THE GENERAL HOSPITAL CORPORATION , THADHANI, Ravi , WOLF, Myles , KNICKERBOCKER, Tanya, Lynn , MACBEATH, Gavin
发明人： THADHANI, Ravi , WOLF, Myles , KNICKERBOCKER, Tanya, Lynn , MACBEATH, Gavin
IPC分类号： C12Q1/00
摘要： The invention relates to methods and compositions for identifying pregnant subjects having, or predisposed to having, gestational diabetes, preeclampsia, and gestational hypertension. The methods are applicable to urine and/or blood samples and can be conducted prior to the third trimester of pregnancy, and as early as the first trimester.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式